Glatiramer acetate and Relapsing-remitting multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Relapsing-remitting multiple sclerosis is reported as a side effect among people who take Glatiramer acetate (glatiramer acetate), especially for people who are female, 30-39 old, have been taking the drug for 2 - 5 years also take Amantadine, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Relapsing-remitting multiple sclerosis when taking Glatiramer acetate. It is created by eHealthMe based on reports of 5,153 people who have side effects when taking Glatiramer acetate from the FDA, and is updated regularly.

What is Glatiramer acetate?

Glatiramer acetate has active ingredients of glatiramer acetate. eHealthMe is studying from 5,158 Glatiramer acetate users. Check the latest studies of Glatiramer acetate.

What is Relapsing-remitting multiple sclerosis?

Relapsing-remitting multiple sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged) is found to be associated with 126 drugs and 178 conditions by eHealthMe. Check the latest studies of Relapsing-remitting multiple sclerosis.

On Jul, 29, 2026

5,153 people reported to have side effects when taking Glatiramer acetate.
Among them, 11 people (0.21%) have Relapsing-remitting multiple sclerosis.

Could Glatiramer acetate cause Relapsing-remitting multiple sclerosis?

Among these 11 people:

How long have people been on Glatiramer acetate when they have Relapsing-remitting multiple sclerosis? *

What is the gender of people who have Relapsing-remitting multiple sclerosis when taking Glatiramer acetate? *

female: 100 %
male: 0.0 %

What is the age of people who have Relapsing-remitting multiple sclerosis when taking Glatiramer acetate? *

What are other drugs people take besides Glatiramer acetate? *

What are other side effects people have besides Relapsing-remitting multiple sclerosis? *

Premature Menopause: 8 people, 72.73%
Disease Progression: 8 people, 72.73%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 2 people, 18.18%
Facial Pain: 1 person, 9.09%
Lymphopenia (an abnormally low level of lymphocytes in the blood): 1 person, 9.09%
Kidney Infection (Pyelonephritis): 1 person, 9.09%
Hepatic Enzyme Increased: 1 person, 9.09%
Hair Loss: 1 person, 9.09%
Gait Disturbance: 1 person, 9.09%
Weakness: 1 person, 9.09%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 36.36%
Trigeminal Neuralgia (a painful condition of the nerve responsible for most facial sensation): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Glatiramer acetate and have Relapsing-remitting multiple sclerosis?

- Check whether Relapsing-remitting multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Glatiramer acetate:

Glatiramer acetate (5,158 reports)

Relapsing-remitting multiple sclerosis treatments and more:

Relapsing-remitting multiple sclerosis (76,275 reports)

How severe was Relapsing-remitting multiple sclerosis and when was it recovered:

Relapsing-remitting multiple sclerosis in Glatiramer acetate

Expand to all the drugs that have ingredients of glatiramer acetate:

Relapsing-remitting multiple sclerosis and drugs with ingredients of glatiramer acetate (61 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Glatiramer acetate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Relapsing-remitting multiple sclerosis:

Relapsing-remitting multiple sclerosis (126 drugs)

Browse all the conditions that are associated with Relapsing-remitting multiple sclerosis:

Relapsing-remitting multiple sclerosis (178 conditions)

Related publications that referenced our studies

Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .
Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .

How the study uses the data?

The study uses data from the FDA. It is based on glatiramer acetate (the active ingredients of Glatiramer acetate) and Glatiramer acetate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.